Communiqués Scienture Holdings, Inc.

Actions

SCNX

US80880X1046

Produits pharmaceutiques

Temps Différé Nasdaq Autres places de cotation 18:23:31 07/07/2026			Varia. 5j.	Varia. 1 janv.
0,3403 ^USD	-1,48%		-2,77%	-33,27%

18/06	Scienture Holdings étend la couverture d'Arbli et renforce son accès commercial	CI
09/06	Scienture Holdings, Inc. obtient le référencement du REZENOPY™ auprès d'un grand assureur national et renforce son équipe commerciale	CI

Communiqués

18/06	SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide	AQ
09/06	SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team	AQ
04/06	SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC	AQ
02/06	SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041	AQ
18/05	SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion	AQ
15/05	Scienture Holdings: Q1 Earnings Snapshot	AQ
07/05	Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline	AQ
06/05	SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041	AQ
15/04	Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement	AQ
06/04	Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead	AQ
30/03	Scienture Holdings: Q4 Earnings Snapshot	AQ
30/03	SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update	AQ
11/03	SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions	AQ
03/02	SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium	AQ
14/01	SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment	AQ
22/12	SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA	AQ
10/12	SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium	AQ
02/12	SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025	AQ
13/11	SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update	AQ
12/11	Scienture Holdings: Q3 Earnings Snapshot	AQ
04/11	SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans	AQ
23/10/25	SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)	AQ
16/10/25	SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers	AQ
08/10/25	SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet	AQ
01/10/25	SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions	AQ